NEW research from Matrix Global Advisors (MGA) finds 9 of the 10 prescription drugs that have increased most in price since 2018 DO NOT have rebates. Learn more about their findings: affordableprescriptiondrugs.org/resources/reba…

.Matrix Global Advisors (MGA)’s latest research finds that among drugs without rebates, price increases ranged over 400% & average price hikes were a whopping 93%. The top drugs with rebates saw much lower price increases: 44% on average. Learn more: affordableprescriptiondrugs.org/resources/reba…

NEW: For lawmakers looking to lower drug costs for patients, Matrix Global Advisors (MGA)’s new report is a must-read. The findings are clear: Congress should to focus on policies that promote competition to lower drug prices, not limit pharmacy benefits affordableprescriptiondrugs.org/resources/reba…

To combat high and rising prescription drug prices, Congress should focus on policies that promote drug competition. More here in new research from Matrix Global Advisors (MGA): affordableprescriptiondrugs.org/resources/reba…

“Look at policies that address the root of the problem: drug companies’ monopolistic pricing power,” says CAPD’s Maura Keefe on Matrix Global Advisors (MGA)’s latest report. Read more: affordableprescriptiondrugs.org/articles/new-r…

.Matrix Global Advisors (MGA)’s latest report: combatting high and pricing prescription drug prices will require Congress to focus on policies that promote drug competition. More on the findings here: affordableprescriptiondrugs.org/resources/reba…

Despite drug companies’ claims that rebates drive up drug prices, a new report from Matrix Global Advisors (MGA) finds that the prescription drugs that have increased most in price DO NOT have rebates. Learn how Big Pharma tries to shift blame for the high drug prices: affordableprescriptiondrugs.org/resources/reba…

Matrix Global Advisors (MGA)’s Alex Brill in a new research report for CAPD: “If Congress wants to lower drug prices, the data shows that targeting rebates will not be effective.” Read the full report: affordableprescriptiondrugs.org/resources/reba…

Read Matrix Global Advisors (MGA)’s latest report for more on how despite Big Pharma’s claims, PBM-negotiated rebates LOWER prescription drugs prices, not raise them. affordableprescriptiondrugs.org/resources/reba…

New report: Before placing limits on the rebates that lower drug prices, Congress should consider the potential harm to patients, taxpayers and the healthcare system. affordableprescriptiondrugs.org/resources/reba…

A new blog by Alex Brill of Matrix Global Advisors (MGA) Biden Budget Proposes a Step Toward Biologic Drug Competition getmga.com/biden-budget-p…

Our latest blog post: getmga.com/biden-budget-p…

Alex Brill , founder and CEO of Matrix Global Advisors (MGA) and former policy director and chief economist for the House Committee on Ways and Means, examines how the insulin market has changed – for the betterment of patients – over the years, underscoring how competition from the free

Tomorrow, the Senate Judiciary Committee will hold a hearing about competition in the prescription drug market. Will Congress finally do something? We wrote about it on our blog, and we'll be watching tomorrow's hearing closely. getmga.com/will-congress-…

Read MGA's new post about the economics of delinking and why this is not good for patients. getmga.com/economics-of-d…

Congress is considering misguided proposals targeting the market-based role of pharmacy benefit companies in the health care system. Learn more: pcmanet.org/pcma-blog/stop…

A new blog by former policy director and chief economist for the U.S. House Committee on Ways and Means Alex Brill, warning against government intervention in the private health market. getmga.com/congress-on-th…

It's been 10 years since the first US biosimilar approval. The second decade of this market is underway, it's important for policymakers to address remaining barriers to a competitive marketplace for biologic drugs. Check out our new paper! getmga.com/wp-content/upl…

.Matrix Global Advisors (MGA) Releases New White Paper on Medicare Price Negotiations and Drug Competition: “If a brand drug’s price could be set by the government prior to generic entry, generic drugmakers’ incentives to undertake the risk and expense associated with bringing a generic to